Rejoni Taps MedTech Veteran John Nealon as CEO to Steer Uterine Health Push

BEDFORD, MA – May 04, 2026 – In a strategic move signaling a shift from clinical development to commercial readiness, Rejoni, Inc. has appointed John Nealon, a seasoned executive in women’s health medical technology, as its new Chief Executive Officer. The appointment comes at a pivotal moment for the Bedford-based company as it navigates the final stages of regulatory approval for its flagship product, the Juveena® Hydrogel System, a novel therapy aimed at preventing a debilitating and often overlooked gynecological condition.

Amarpreet Sawhney, PhD, the serial entrepreneur who founded Rejoni in 2020 and has led it as CEO, will transition to the role of Chairman of the Board. He expressed his full confidence in the leadership transition, underscoring the strategic importance of Nealon’s expertise for the company's next chapter.

A Proven Leader for a Pivotal Moment

John Nealon is not a newcomer to the complexities of the women’s health market. With over two decades of experience, he has built a reputation for transforming innovative medical concepts into commercial successes. His most recent and notable achievement was as the Founder, President, and CEO of UroCure LLC. At the helm of the Minneapolis-based company, Nealon successfully guided a portfolio of innovative sling systems for female stress urinary incontinence through the entire product lifecycle.

Under his leadership, UroCure secured critical FDA clearances for its ArcSP and ArcTO sling systems in September 2022 and cultivated a strategic sales partnership with LiNA Medical. This journey culminated in the successful acquisition of UroCure by LiNA Medical in January 2026, a testament to Nealon's ability to build value and execute a successful exit strategy. His earlier career includes senior leadership roles at American Medical Systems (AMS), where he managed one of the industry's leading portfolios in gynecology and urology, providing him with deep insights into the very market Rejoni aims to disrupt.

This track record is precisely what Rejoni was seeking as it prepares to bring Juveena to market. “As Rejoni advances toward FDA approval for the Juveena® Hydrogel System, I am thrilled to welcome John Nealon as our new CEO,” said Dr. Sawhney in a statement. “His decades of experience leading women’s health businesses, his proven ability to navigate the complexities of medical device commercialization, and his genuine passion for improving outcomes for women make him the ideal leader to bring Rejoni into its next chapter.”

Targeting an Unseen Burden in Women's Health

The technology Nealon will now champion, the Juveena® Hydrogel System, addresses a significant unmet need: the prevention of intrauterine adhesions (IUAs), also known as Asherman's syndrome. These bands of scar tissue can form inside the uterus following common gynecological procedures like dilation and curettage (D&C), fibroid removal, or C-sections.

While often underdiagnosed, the consequences of IUAs can be devastating. They are a leading cause of secondary infertility, recurrent pregnancy loss, and chronic pelvic pain, creating a profound physical and emotional burden for millions of women worldwide. Current management often involves complex surgical interventions to remove the adhesions, which themselves carry a risk of recurrence.

Rejoni’s Juveena system offers a proactive, preventive approach. It is a proprietary hydrogel designed to be instilled into the uterus transcervically after a surgical procedure. The gel acts as a temporary, absorbable barrier, physically separating the uterine walls during the critical healing period to prevent the scar tissue from forming. By intervening before adhesions can develop, Rejoni aims to preserve uterine function, protect fertility, and prevent the cascade of complications associated with IUAs. This focus on a preventative biomaterial represents a potential paradigm shift away from reactive surgical treatment.

Navigating the Final Hurdles to Market

With Nealon at the helm, Rejoni's primary focus is clear: navigating the final leg of the regulatory journey and preparing for a successful commercial launch. The Juveena® Hydrogel System is currently classified as an investigational device and is pending FDA approval, a high-stakes process that requires meticulous data and strategic engagement. Nealon’s direct experience in securing FDA clearance for UroCure’s devices will be an invaluable asset in this final push.

In his own words, Nealon is ready for the challenge. “I am honored and energized to join Rejoni at this pivotal moment in the company’s journey. Uterine health has been an underserved area for far too long, and Rejoni’s mission to protect, preserve, and heal the uterus resonates deeply with me,” he stated. “I look forward to partnering with Amar, the leadership team, and our investors to advance the Juveena Hydrogel System through the regulatory process and into the hands of physicians and patients who can benefit from it.”

The transition from a founder-led research and development company to a commercially-focused entity is a classic, yet critical, inflection point for any clinical-stage firm. By bringing in a seasoned commercial leader like Nealon, Rejoni’s board is making a clear statement about its ambitions. The move allows Dr. Sawhney to continue providing strategic vision as Chairman while empowering Nealon to build the commercial infrastructure necessary for market entry, including sales, marketing, and distribution strategies. This division of roles positions Rejoni to effectively tackle the dual challenges of completing its clinical program and preparing the market for a first-of-its-kind therapeutic solution to a long-neglected problem in women's health.